Replies to post #522990 on NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

I agree. It’s kind of baked in now, unfortunately. Unless there is some compelling narrative around the data that was not highlighted during the presentations at NYAS and by KA and LL in the last few months.

[Poor Man -]

Tend to agree the journal article will not have a significant influence on the share price; maybe it gets us back above $1 plus. The article is more of a catalyst to get to the more important matters of an up list and to satisfying a condition for a partnership.

The key will be how quickly they transition from the journal article to announcement of the ASM and proxy, along with the other events above. They’ve certainly had enough time to prepare, so the ASM and proxy should be announced and available within a few days afterwords.

ATL, I don't doubt the importance of the journal article, or the importance it would have in validating and verifying the DCVax-L trial results. I just doubt the article will have the significant impact on the NWBO share price that if would have if accepted and published in a shorter time frame once the initial phase 3 results were announced.

[HappyLibrarian]

When the journal article finally does come out Adam Feuerstein could probably write an article saying “NWBO journal article rehashes old news” and the markets would buy that narrative.

We will then go from the journal article bolstering the share price and chances of approval to approval being needed to cover (from an investor though not scientific perspective) the journal article.

It’s a stunning reversal.

Hopefully NWBO is ready for this and has finally learned from Buzdargate and May 10th and will b more effective with public and investor relations if and when Mr. Feuerstein speaks his piece again.